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REGULATING BY REPUTE
David Zaring*
REPUTATION AND POWER: ORGANIZATIONAL IMAGE AND PHARMA-
CEUTICAL REGULATION AT THE FDA. By Daniel Carpenter.
Princeton and Oxford: Princeton University Press. 2010. Pp. xx,
802. Cloth, $78.50; paper, $35.
INTRODUCTION
Is regulation a hopeless cause? Many thoughtful observers spend a lot of
time enumerating all of the reasons why it is doomed to fail. The entire field
of public choice, with impeccable logic, posits the likely corruption of every
bureaucrat.' And if corruption cannot explain the failure of regulation, the
atrophy that comes from lack of competition-there is just one government,
after all, and it does not have a profit motive-may be just as rich a vein to
mine.' It could also be that the legal system itself, with its myriad complexi-
ties, checks, and procedural requirements, may ossify to the point of
strangulation whatever is left of the governance project that capture and
incompetence have not already disposed of.3
* Assistant Professor of Legal Studies and Business Ethics, The Wharton School of
the University of Pennsylvania. Thanks to Daniel Carpenter, Chris Carrigan, Cary Coglianese,
Ted Ruger, and Pamela Steiner for helpful comments.
1. Several economic Nobel prizewinners have earned some of their plaudits for the
development of this critique. See generally JAMES M. BUCHANAN & GORDON TULLOCK, THE
CALCULUS OF CONSENT (1962) (providing an exploration of the rules governing legislative
decisionmaking based on the assumption that decisionmakers act in their own self-interest);
Gary S. Becker, A Theory of Competition Among Pressure Groups for Political Influence, 98
Q.J. ECON. 371 (1983); George J. Stigler, The Theory of Economic Regulation, 2 BELL J.
ECON. & MGMT. ScI. 3 (1971). For an overview, see David A. Skeel, Jr., Public Choice and
the Future of Public-Choice-Influenced Legal Scholarship, 50 VAND. L. REV. 647 (1997)
(reviewing MAXWELL L. STEARNS, PUBLIC CHOICE AND PUBLIC LAW: READINGS AND COM-
MENTARY (1997)).
2. For a discussion by another economics Nobel prizewinner of why bureaucracies
generally will be inefficient, see generally F. A. HAYEK, THE ROAD TO SERFDOM 138-56 (50th
ann. ed. 1994).
3. "Ossification," a geological term, refers to the canonical article in this area. See
Thomas 0. McGarity, Some Thoughts on "Deossifying" the Rulemaking Process, 41 DUKE
L.J. 1385, 1453 (1992) (concluding that in complex scientific cases, courts should apply a
pass/fail standard to grade the agency rather than the stringent procedural reviews then in
vogue); see also Thomas 0. McGarity, The Courts and the Ossification of Rulemaking: A
Response to Professor Seidenfeld, 75 TEX. L. REV. 525, 533-36 (1997) (defending the ossifi-
cation thesis); Richard J. Pierce, Jr., Seven Ways To Deossify Agency Rulemaking, 47 ADMIN.
L. REV. 59, 65 (1995) ("With the exception of a few agencies, the judicial branch is responsi-
ble for most of the ossification of the rulemaking process."). But see Jason Webb Yackee &
Susan Webb Yackee, Administrative Procedures and Bureaucratic Performance: Is Federal
Rule-making "Ossified"? 20 J. PUB. ADMIN. RES. & THEORY 261, 261-62 (2010) (utilizing
data that covers all active federal rule-writing agencies from 1983 to 2006, and concluding
1003
Michigan Law Review
And yet governance, against all these odds, thrives everywhere that
markets and people thrive.4 It is something of a puzzle, really, given all of
the excellent reasons why regulation should be nothing more than zero-sum
cupidity.5 Is there some other reason to trust governance, despite the ease
with which regulators may be captured by rent-seekers, dulled by monopo-
lization, and stayed by process?
Daniel Carpenter6 thinks so. His history of the pharmaceutical arm of
the Food and Drug Administration ("FDA"), Reputation and Power: Organ-
izational Image and Pharmaceutical Regulation at the FDA, concerns a
classic regulatory enterprise-the government's effort to ensure that its citi-
zens consume safe and effective drugs-that, he argues, went well for
decades. His definitive account blends political science theory with a granu-
lar retelling of the challenges and achievements of American
pharmaceutical regulation. It is meant to be the ur-book on the subject, a
reference work that obviates the need for more digging by other scholars
into the FDA's pharmaceutical history.
But Reputation and Power is not just about one product line regulated
by one agency. I read the book not as a story about drug law (or at least not
that the results "largely disconfirm the ossification thesis"). For a broader discussion, see Wil-
liam S. Jordan, III, Ossification Revisited: Does Arbitrary and Capricious Review
Significantly Interfere with Agency Ability To Achieve Regulatory Goals Through Informal
Rulemaking?, 94 Nw. U. L. REV. 393,402 (2000).
4. Or so a number of prominent economists, from both the right and the left, have
concluded. See, e.g., Daniel Kaufmann, Governance Redux: The Empirical Challenge (Oct.
2003) (unpublished manuscript), available at http://papers.ssrn.com/sol3/papers.cfm?
abstractid=541322 (noting "a very high correlation between good governance and key devel-
opment outcomes across countries"). For a discussion of Kaufmann's work from a legal per-
perspective, see Chantal Thomas, Law and Neoclassical Economic Development in Theory
and Practice: Toward an Institutionalist Critique of Institutionalism, 96 CORNELL L. REV.
967, 1010-11 (2011). The so-called "LLSV hypothesis," named for its authors, also suggests
that regulation, or at least good governance and strong legal protections, is an important pre-
condition to prosperity. See Rafael La Porta, Florencio Lopez-de-Silanes, Andrei Shleifer &
Robert W. Vishny, aw and Finance, 106 J. POL. ECON. 1113, 1152 (1998). For a discussion
of this hypothesis, see Stephen J. Choi, Law, Finance, and Path Dependence: Developing
Strong Securities Markets, 80 TEx. L. REV. 1657, 1727 (2002), and for a critique and another
summary, see Claude Mdnard & Bertrand du Marais, Can We Rank Legal Systems According
to Their Economic Efficiency?, 26 WASH. U. J.L. & POL'Y 55, 59 (2008) ("[LLSV] explicitly
assumes that there is a close relationship between 'good' institutional design and economic
development, and that countries with poor investor protections, either because of their legal
system or because of the enforcement rules of this system, severely suffer in their economic
dynamics.").
5. This sort of rational choice analysis underlies the elements of positive political
theory that have been applied to administrative law. See Matthew D. McCubbins et al., Struc-
ture and Process, Politics and Policy: Administrative Arrangements and the Political Control
of Agencies, 75 VA. L. REV. 431, 434-35 (1989) (describing how Congress controls agencies
through judicial review or through warning systems designed to facilitate congressional over-
sight); see also Daniel B. Rodriguez, The Positive Political Dimensions of Regulatory Reform,
72 WASH. U. L.Q. 1, 43 (1994) ("Positive political theory describes regulatory policymaking
as a part of a world in which political actors function within institutions rationally and strate-
gically in order to accomplish certain goals." (footnote omitted)).
6. Freed Professor of Government, Harvard University.
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only that), but as an identification of a model of governance that could ap-
ply not just to medicines, but also to all sorts of consumer products, and
perhaps even more broadly to agencies engaged in financial regulation, law
enforcement, and other fundamental projects of the administrative state.
Carpenter's history offers insights relevant to agency design, to the im-
portance of image in administration, and, I think, to attempts to justify the
regulation of anything.
In particular, Reputation and Power offers two valuable insights to those
interested in the progress of the legal enterprise of regulation. First, its cen-
tral claim-that the good reputation of the FDA was a critical component of
its success-offers a chance to evaluate the merits of relying on reputation
as the secret sauce that promotes law-abiding behavior. Reputation, some-
times defined variously, is an increasingly popular explanation for legal
compliance when a tally of the more immediate and tangible costs and ben-
efits would suggest that noncompliance or shirking is the more rational
choice; indeed, a number of scholars have argued that good reputation is the
explanation for effective regulation, even in the face of the rent-seeking and
overlegalization that would seem bound to stymie it every time. Because
Carpenter argues that reputation explains much of the FDA's success, his
monograph permits consideration of the complex relationship between
reputation and legal compliance.
Second, by delving into what the agency did once it was given the au-
thority to permit or reject the sale of drugs in the American market,
Carpenter offers an account of what happens in agencies after administra-
tive law stops its usual inquiry--or, at least, after it did so in the case of the
FDA.7 The lawyers sorted out what the agency could do; Carpenter's history
of the FDA evaluates what the agency did do-he studies the ordinary gov-
ernance of drug approvals that ensued after Congress's direction was
interpreted and after the courts decided to defer to the scientists in the agen-
cy.8 These postlitigation bureaucratic processes often go beyond the scrutiny
of administrative lawyers interested in the judicial supervision of agencies,
but sorting out what agencies actually do with their powers is critical to any
useful understanding of the purpose of judicial and legislative oversight.
Carpenter's account takes the legal authority that Congress gave to the FDA
as a precondition to understanding it, rather than as the end of the analysis.
7. See James T. O'Reilly, Losing Deference in the FDA's Second Century: Judicial
Review, Politics, and a Diminished Legacy of Expertise, 93 CORNELL L. REV. 939, 940 (2008)
(describing the long history of judicial deference enjoyed by the FDA).
8. See Richard A. Merrill, The Architecture of Government Regulation of Medical
Products, 82 VA. L. REV. 1753, 1775 n.68 (1996) ("To bring a successful challenge to the
terms FDA set the sponsor would have to convince a court that the agency had acted arbitrari-
ly or without factual basis. This has proved nearly impossible." (citations omitted)). Courts
have been much less deferential to the FDA's labeling and marketing supervision, to say noth-
ing of the food safety division of the agency. See, e.g., Wash. Legal Found. v. Friedman, 13 E
Supp. 2d 51, 74 (D.D.C. 1998), amended sub nom. Wash. Legal Found. v. Henney, 56 E
Supp. 2d 81, 88 (D.D.C. 1999), vacated in part, 202 F.3d 331 (D.C. Cir. 2000) (invalidating
the FDA's effort to restrict pharmaceutical companies from discussing off-label uses of drugs).
1005April 2012]
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In this Review, I first discuss Carpenter's story about the way that repu-
tation and power interacted to the benefit of the FDA's regulatory mission.
In Part II, I consider the merits of reputation as a governance tool, which I
believe are real but limited. Carpenter is right to recognize that reputation
gets agencies breathing room from courts and Congress, and motivates em-
ployees-if anything, it is important to recognize that there are many other
nonpecuniary reasons why regulators might perform their jobs well, and
that reputation should not stand in for all of them. In Part III, I offer some
other criticisms of the Carpenter book, which focus chiefly on its doorstop
ambitions. Part IV offers some thoughts about the relationship between the
ordinary governance that is the subject of his history and the sort of govern-
ance that lawyers study. A richer understanding of the incentives of
regulators, and an awareness of the sheer quantity of work that they do out-
side of the courts, underscores some of the limitations of the naively cynical
story about the doomed governance project. Regulation is hardly perfect,
but, really, it is a lot like work in any large organization: it is capable of tri-
umphs and failures, and it can-if designed well, to meet a need-be made
effective.
I. REPUTATION AND POWER AT THE FDA
In the first decades of the twentieth century, Americans consumed
aggressively-marketed medicines that did not cure anything, and evaluated
these medicines through strategies of self-help and personal experimenta-
tion. Today, the FDA only permits medicines that are proven to be safe and
effective to be sold; the fly-by-night patent medicine outfits are gone, and
health care is provided by doctors and scientists. Life expectancy, in the
meantime, has skyrocketed, and intractable diseases, ranging from tubercu-
losis to polio to AIDS, have been made tractable. By mediating the
relationship between therapeutic drugs and their potential consumers, the
FDA has played a critical role in this remarkable evolution in drugs, sci-
ence, health, and business. It famously kept thalidomide out of the
American market, saving the country from the tragic deformed births in
Germany and Australia, where the drug was widely prescribed to mitigate
morning sickness.9 It kept the ineffective cancer therapy Laetrile from
American shelves in the face of a great deal of public pressure to approve
the drug.10 And it evinced flexibility in the face of AIDS, which looked like
9. Chapter 4. The cover of Carpenter's book depicts Frances Kelsey, the FDA official
famous for rejecting the application to use the morning sickness drug in the American market.
10. Pp. 410-28. In United States v. Rutherford, 442 U.S. 544, 551 (1979), the Supreme
Court ruled that terminal cancer patients had no right to use Laetrile absent FDA approval, a
victory for the agency, which had to endure a great deal of public pressure to legalize the
drug-including from actor Steve McQueen. McQueen took a course of Laetrile in Mexico
and claimed that he was happy with the results; he later died of cancer in 1980. Pp. 424-25.
For a discussion of the McQueen case and the Laetrile controversy, see Jerry Menikoff, Be-
yond Abigail Alliance: The Reality Behind the Right To Get Experimental Drugs, 56 U. KAN.
L. REV. 1045, 1046-47 (2008). According to Carpenter, "In resisting the most popular alterna-
1006 [Vol. 110:1003
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it would be a death sentence for hundreds of thousands of Americans and
ruination for the agency's careful but slow approval process (Chapter Six).
How did it manage all of these accomplishments?
In Carpenter's view, the agency benefitted from the initial grant of
strong legal authority--especially the authority to serve as a gatekeeper
over new drugs (p. 16). But that power was critically enhanced by the agen-
cy's growing reputation for effectiveness, which it built by transforming its
drug approval process into something that looked like state-of-the-art scien-
tific research. Over the course of the forty years following World War II, the
agency required randomized controlled experiments-three-stage and, in
some cases, five-stage testing processes-and, at least in theory, continued
surveillance of drugs after approval to be sure that they were working as
intended (Chapter Nine).
The FDA also built a strong reputation. Reputation can be defined capa-
ciously, and Carpenter embraces that capaciousness, for better and for
worse. Sometimes, reputation affects public reliance on agency work, and
sometimes reputation affects what experts in the field, from journalists to
advocates to scientists to businesspeople, think about an agency's work (pp.
33-34). In the former cases, reputation leads to support in the political
arena; in the latter, to acquiescence to agency decisions by the relevant
stakeholders (pp. 45-60). Reputation also appears to have had an effect on
the courts too-they have adopted a multidecade record of deference to the
FDA's pharmaceutical decisions, lasting from the quiescent 1950s through
the activist 1970s to today (pp. 45-60).
But if reputation contains multitudes, the idea, for each of these audi-
ences, is that the agency's legal strength may be paired with an extralegal
fillip that turns mere authority into something worthy of respect. Reputation
can lead to virtuous circles of ever-better regulation: the agency itself be-
came motivated to meet high scientific and safety standards because such
standards were expected and relied on by everyone else (pp. 55-56). This
account might be characterized as something of an exercise in constructivist
political science-the idea that ideas and intangibles can shape other tangi-
ble facts, like power and resources.I
Carpenter begins his book with an account of the gradual evolution of the
FDA between the 1938 Food, Drug, and Cosmetic Act's creation of its gate-
keeper role, to its 1961 triumph in banning thalidomide from the American
market, followed quickly by 1962 legislation institutionalizing and expanding
tive remedy in a generation, the Administration had witnessed its power confirmed in tandem
with its reputation." P. 428.
11. Although I associate the constructivist element of political science mostly with a
strand of international relations heterodoxy, see, e.g., James Fearon & Alexander Wendt, Ra-
tionalism v. Constructivism: A Skeptical View, in HANDBOOK OF INTERNATIONAL RELATIONS
52 (Walter Carlsnaes, Thomas Risse & Beth A. Simmons eds., 2004), it has found its way into
the international legal literature as well, see Ryan Goodman & Derek Jinks, How To Influence
States: Socialization and International Human Rights Law, 54 DUKE L.J. 621 (2004).
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its watchdog status (pp. 238-60). The approach is historiographical. 12 While
others see a sharp break between a quiescent agency before the thalidomide
decision and the 1962 amendments and a fearsome agency after them, Car-
penter argues that the FDA's adoption in the 1940s and 1950s of best
scientific practices regarding the clinical evaluation of new medicines made
the difficult decision to ban a popular drug like thalidomide possible.13
In this telling, a necessary, but not sufficient, initial step in building the
FDA's reputation turned on the power that Congress gave the agency (pp.
74-75). Before 1938, the FDA could remove only demonstrably dangerous
medicines from the shelves, and, although the New Deal was a good time
for agencies to receive broad grants of authority from Congress, the FDA's
acquisition of a power to pass on the dangerousness of medicines before
they were marketed to consumers was no sure thing (pp. 80-85). As is often
the case with regulatory reform, it was a disaster that won the agency its
broad new responsibilities-specifically, the deaths of at least seventy
Americans to an antifreeze-laced patent medicine produced by the Massen-
gill Company of Tennessee.1 4 The resulting legislation turned the FDA's
veto power into an assent requirement, and it also changed the mood of
pharmaceutical regulation. The deferential decision by the Supreme Court
in United States v. Dotterweich affirmed that the agency and the Department
of Justice could broadly sanction drugmakers found to produce adulterated
or dangerous products.I Accordingly, although the importance of reputation
for regulatory effectiveness animates Carpenter's account, the legal powers
that the 1938 Act granted came first.
That power was confirmed between World War II and 1962; the FDA
almost never lost in court during that period (p. 362). The result was the
creation of something of an almighty agency, with little supervision by the
courts, Congress, or, apparently, the rest of the executive branch.
One can imagine disastrous or happy outcomes ensuing from such lib-
erty, but Carpenter's account does not explain why the agency, given its
legal power to regulate in any of a number of different ways, chose to
12. By historiography, I mean the somewhat traditional historical contests between
accounts of when an important change occurred. See Buckner F. Melton, Jr., Clio at the Bar:
A Guide to Historical Method for Legists and Jurists, 83 MINN. L. REV. 377, 388 (1998) (de-
fining historiography as "a study of the history of the writing of history").
13. Carpenter argues that the critical moment in the empowerment of the FDA occurred
not between 1960 and 1962, when the FDA banned thalidomide and received new authority in
the 1962 Kefauver-Harris Amendments to its governing statute, but rather more gradually
before then as the agency engaged in increasingly scientific practices for drug evaluations, an
evolving postwar trend that stemmed from the critical gatekeeping role for new drugs that it
assumed in 1938. Pp. 119-23.
14. P. 87. A staff writer for the FDA suggests that over 100 people died after taking the
drug. Carol Ballentine, Taste of Raspberries, Taste of Death: The 1937 Elixir Sulfanilamide
Incident, FDA CONSUMER, June 1981, available at http://www.fda.gov/AboutFDA/
WhatWeDo/History/ProductRegulation/SulfanilamideDisaster/default.htm.
15. 320 U.S. 277 (1943) (upholding strict liability against corporate executives, namely,
the president of a firm found to have mislabeled drugs); see also pp. 116-17 (citing Dotter-
weich, 320 U.S. 277).
1008 [Vol. 110:1003
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adopt best scientific practices for drug approval. In addition to the thalido-
mide success, though, the implementation of the 1938 legislation resulted in
a growth in the scientificness-and burdensomeness-of FDA approvals.
Randomized control trials were required. Data were expected to be shared.
Three-phase experiments including clinical trials and human subject tests
became the sine qua non of what the FDA did. 16 To Carpenter, the important
historiographical fact about these innovations is that they were instituted
before the banning of thalidomide-that is, the FDA became the modem
and effective agency he admires not because it happened to make a right
choice on a dangerous drug in 1961, but rather because it adopted best sci-
entific practices to inform the implementation of the authority given it in
1938.
After the thalidomide episode, a heyday of the FDA ensued, one that
lasted between 1963 and approximately 1986, a period in which, despite
debates over whether the agency was slowing the introduction of new thera-
peutic pharmaceuticals, its word was respected law and all but judicially
irreversible. As Carpenter observes, the FDA's approach to pharmaceutical
approval "became normal, as authority was converted into patterns of proto-
col, expectation, and practice, and as everyday life in the modern
pharmaceutical world was restructured" (p. 299). During this period, the
FDA approved a universe of controversial drugs, including contraceptives
such as the Pill, without rousing the ire of the public or suspicions of politici-
zation (pp. 185-88). Aggrieved stakeholders, if they wished to reverse an
agency decision, were forced to adopt a rather strange, generally ineffective
set of arguments that turned on the process of approval or denial, rather than
on the basic science behind the drugs (pp. 465-68). Moreover, they usually
had to make this case to the agency itself, rather than to the courts, which, if it
led to anything, led only to a further elaboration of the protocols required be-
fore a manufacturer could hope to win approval of a new drug (pp. 359-62).
In Carpenter's view, the period following the apogee of the agency's
power has been marked by increasingly vigorous debates about how that
power has been deployed. Part of this debate has been a straightforward
conversation about the efficacy of government oversight, one increased dur-
ing antiregulatory ferment in the Bush Administration-this often took the
form of handwringing over the amount of time taken by the agency to ap-
prove new drugs (p. 741). But somewhat more subtly, the combination of
reputation and gatekeeping power has led to a focus on the question of ap-
proval, to the detriment of postapproval monitoring to see if the drugs have
actually worked (pp. 586-87). Accordingly, "[s]ince the 1960s at latest,
critics and observers of U.S. pharmaceutical regulation have targeted the
post-market surveillance system for complaints. And their conclusions,
while varied in some respects, have often revisited the perceived conflict
between pre-market and post-market processes" (pp. 588-89). The post-
market critique now has a poster drug in Vioxx, the heart disease medication
16. P. 229. For another discussion of the evolution of the new drug approval system
after 1982, see Merrill, supra note 8, at 1768-1800.
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that, effective as it was, was not safe for all patients, as it turned out after
the FDA approved it (pp. 737-43). For Vioxx, it was the tort system, rather
than the FDA, that performed much of the critical postmarket regulatory
work. 1 7 And so the FDA's reputation has grown more contested, even as its
legal authority remains unchanged. To Carpenter, this suggests that the
overall effectiveness of the agency, which depends both on power and repu-
tation, could now be threatened.
II. REPUTATION AS A LEGAL MATTER
In Carpenter's view, the reasons for the FDA's successful record are
rooted in the reputational incentives of the regulators who worked for it, the
respect its reputation engendered in other stakeholders in pharmaceutical
regulation, and the institutional decision to place the agency as the gate-
keeper through which all new drugs must pass before going to market.18
While lawyers understand the implications of gatekeeping authority well,
Carpenter's emphasis on reputation is different precisely because it does not
depend on legal authority-although reputation can, in his understanding,
affect that authority. Reputation incentivizes regulators to pursue their mis-
sion against pushback from the industry and criticism from Congress, and to
do so emboldened by the support that the public can provide to a techno-
cratic, jargon-ridden institution. Moreover, reputation, in the view of
Carpenter and others, can create virtuous circles: regulators want to be seen
as doing a good job, and the more plausible the story about why they may
be doing a good job, the more likely that the agency's work will be met with
respect. 9 This dynamic encourages successful regulatory interventions, fol-
lowed by increasing respect from the players in the political or regulatory
process. For the FDA, the happy reputation story was grounded in an ap-
proach to regulation that turned on scientific best practices that were
overseen and administered by good scientists. Indeed, Carpenter even sug-
gests that FDA regulators became willing to trade leisure and the lucre of
17. For a critical evaluation of the FDA's role in the Vioxx controversy, see David A.
Kessler & David C. Vladeck, A Critical Examination of the FDA's Efforts To Preempt Failure-
To-Warn Claims, 96 GEO. L.J. 461, 465 (2008) ("Recent regulatory failures, such as the
agency's ineffectual response to Vioxx, have demonstrated the FDA's shortcomings .... ").
18. It is worth noting that this gatekeeping function is relatively rare in administrative
agencies. The branch of the FDA regulating food does not sit in judgment of novel foodstuffs
before they may be marketed to consumers, nor does the medical device supervisor. See Mer-
rill, supra note 8, at 1800-35 (discussing the fact that the FDA does not have stringent
premarket regulations for medical devices). And financial regulators, to take another example,
have no such gatekeeping oversight over new financial products, even after the Dodd-Frank
Act's creation of a consumer protection regulator that might, in theory, be able to take on such
a job. Schan Duff, Consumer Financial Protection After Dodd-Frank (Dec. 21, 2010) (un-
published manuscript) (on file with author).
19. See generally JAMES Q. WILSON, BUREAUCRACY: WHAT GOVERNMENT AGENCIES
DO AND WHY THEY Do IT (1991); Mark Seidenfeld, Why Agencies Act: A Reassessment of
the Ossification Critique of Judicial Review, 70 OHIO ST. L.J. 251 (2009).
1010 [Vol. 110:1003
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the revolving door for those reputational benefits. 20 He thinks that this repu-
tation for effectiveness and mission control characterized the FDA from the
1930s until at least the 1990s.1'
Reputation is a common recourse of rationally inclined legal theorists
who wish to explain why legal projects work, even in the face of public
choice reasons why they should not. Andrew Guzman has argued that repu-
tation is the reason why states comply with international law, even when
noncompliance would be in keeping with their short-term interests.2 1 Jeffrey
Lax has argued that reputation-building explains some of the strategic vot-
ing in which justices engage when making certiorari decisions.23 Securities
and Exchange Commission ("SEC") officials tout reputation as one of the
reasons why capital market intermediaries are likely to comply with the
agency's regulations. 24 And, of course, reputation fuels Carpenter's domes-
tic administrative law story.
Is reputation the secret sauce that explains why governance works where
short-term interests or pure public choice analyses would doom it to failure?
In my view, if reputation is defined parsimoniously, the way that many
20. P. 66 ("[O]nce recognized, officials with authority in an organization may take
measured steps to protect, maintain, and enhance [the organization's reputation]. This reputa-
tion-protection imperative has governed and animated the FDA's behavior in pharmaceutical
regulation for much of the last half-century."). For a discussion of how Carpenter's vision of
reputation might affect these sorts of internal motivations, see Steven Teles, Brains on Drugs,
WASH. MONTHLY, May/June 2010, at 48-52 (reviewing Reputation and Power). Carpenter
made similar arguments in his first book, where he argued that bureaucratic autonomy is
"forged" when agency leaders are able to nurture reputations for effectiveness that suggest
that they have unique organizational capabilities. DANIEL P CARPENTER, THE FORGING OF
BUREAUCRATIC AUTONOMY 353 (2001) (arguing that autonomy arises "when agency leaders
build reputations for their organizations-reputations for efficacy, for uniqueness of service,
for moral protection, and for expertise").
21. In the aftermath of the Vioxx withdrawal, however, "the U.S. Food and Drug Ad-
ministration... lost some of its scientific and consumer protection luster." P 738.
22. See ANDREW T. GUZMAN, How INTERNATIONAL LAW WORKS 71-72 (2008).
23. Jeffery R. Lax, Certiorari and Compliance in the Judicial Hierarchy: Discretion,
Reputation, and the Rule of Four, 15 J. THEORETICAL POL. 61 (2003), available at http://
www.columbia.edu/-jrl2124/Certiorari%20and%2OCompliance%20(Lax,%20JTP).pdf.
24. Paul F. Roye, the former director of the SEC Division of Investment Management,
argued as follows:
A compliance failure can lead to bad publicity and embarrassment, which can permanent-
ly damage a firm's reputation and ultimately lead to an erosion of its client base. The end
result will be lower profitability and private lawsuits. In short, a weak and ineffective
compliance system can spell disaster for an adviser.
Paul F. Roye, Meeting the Compliance Challenge, Remarks Before the Investment
Counsel Association of America (Apr. 23, 1999), available at ttp://www.sec.gov/news/speech/
speecharchive/1999/spch271.htm. For a discussion of the importance of reputation to the
SEC's compliance efforts, see H. Lowell Brown, The Corporate Director's Compliance Over-
sight Responsibility in the Post Caremark Era, 26 DEL. J. CORP. L. 1 (2001); James Rathz,
Compliance as the Competitive Differentiator, 12 Duo. Bus. L.J. 13, 24-25 (2009) ("If a
particular compliance metric included in the compliance story line were to deteriorate to vul-
nerability or deficiency status, the public message could be significantly marginalized, thereby
introducing increased reputation risk to the firm." (footnote omitted)).
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aficionados do with rational choice stories about the government, then repu-
tation alone cannot explain all the useful regulatory achievements in the
face of the usual self-interested incentives to shirk, seek rents, and so on. It
cannot serve as a shorthand for all the difficult-to-capture reasons why
anyone might choose to perform his or her job capably or comply with legal
obligations, although that would seem to be the implication of a rational
choice paradigm in administrative law that seeks to explain everything
through the lens of self-interest, how ever broadly characterized. People-
even government bureaucrats-do not simply seek to win the approval of
others, pay, or leisure from their jobs. Regulators often perform ably for
nonreputational reasons too-because it gives them a sense of self-worth,
because they are interested in the subject matter of what they do, or because
they feel a kinship with those whom their agency is meant to protect. But
the new enthusiasm for reputation as a way out of the rational choice/public
choice trap for regulatory enterprises elides these other perfectly plausible
non-self-maximizing welfarist reasons that might secure a competent regu-
latory effort by a responsible government.
Accordingly, the recent affection for reputation among scholars might
be most useful as a gateway drug for reputation's consumers in the rational
choice community, a bridge to take them from self-interest alone toward
more nuanced appreciations for social and personal value that bolster legal
compliance in a world in which self-interest alone inevitably dictates shirk-
ing, noncompliance, and corruption.
Moreover, a strong regulatory reputation should not be viewed as a pan-
acea-other agencies have enjoyed elite-level reputations only to make
elite-level mistakes. Consider financial regulation, which has a history of
terrible errors made by highly reputed regulators. Liaquat Ahamed's Pulitz-
er Prize-winning Lords of Finance: The Bankers Who Broke the World is
about the failed efforts of four central banks to provide stability to the West-
ern economy before the Great Depression.25 Ahamed observes:
In the 1920s, [a] group of high financial officials, ... dubbed by the press
the "Most Exclusive Club in the World," ... sought to manage the interna-
tional financial system. But, instead of averting a catastrophe and saving
the world, the committee from the 1920s ended up presiding over the
greatest collapse that the global economy has ever seen.2 6
I view Carpenter's valuation of reputation to be something that regime
designers might consider in other contexts, but historical experience sug-
gests caveats. The work done by Ahamed's central bankers represented one
of the first efforts to create a cross-border regulatory enterprise, and the sto-
ry of how central bank coordination developed in the early part of the
twentieth century still matters today. Their sort of informal regulatory coop-
eration, given its uneven legal support, might seem to be a strong candidate
25. LIAQUAT AHAMED, LORDS OF FINANCE: THE BANKERS WHO BROKE THE WORLD
429-31 (2009).
26. Id. at 506-07.
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for looking to foster its reputation to enhance its compliance pull. But esprit
de corps in the past meant the overcommitment by smart, independent, and
respected central bankers to a ruinous ideal-strong currencies, backed by
gold-in the face of mounting evidence that the gold standard was harming
economic growth.2 7
The reputation won by the FDA in Carpenter's account led it to enjoy a
substantial degree of autonomy. But checks on autonomy have their ad-
vantages; there are risks to groupthink, and if reputation clears the field of
dissent, then a regulatory project can go as wrong as did the project to de-
fend the gold standard.
Reputation may thus be a regulatory tool best deployed for limited pur-
poses. While it may usefully stiffen the spines of enforcement-oriented
regulators, it does not clarify a mission or assist much in the making of good
policy decisions. Reputation is, at best, an enhancement of regulation, rather
than a guarantee of the quality of the ends to which that reputation is put.
III. CAVILS AND CRITICISMS
Carpenter has written a definitive, but methodologically eclectic book:
the account is historical and the constructed reputation story would not look
outlandish to literature scholars, but the storytelling is also accompanied by
quantitative research.28
It is all keenly observed, but it errs on the side of overexhaustiveness.
There are so many facts! In the service of providing the prospective con-
sumer with a sense of the feel of the book, I used a random number
generator to pick out five pages from which I extracted representative sen-
tences, which might then be divided into categories. There are insightful, if
not central, observations; minute details that tend to be too comprehensive;
and occasionally an entertaining mixture of both. For example, Carpenter
observes that by "delegating [research protocol inspections] to the [Institu-
tional Review Boards], a resource-poor agency was able to effect a vast
expansion in its governance of medical research while effecting minimal
direct intrusion into clinical settings" (p. 567). That observation is an im-
portant window into not just pharmaceutical approval, but also a shift in the
nature of oversight of academic research itself. Similarly, Carpenter pro-
vides this interesting observation about nothing less than the
weltanschauung of the average American over time: "The transformation of
'citizen' to 'consumer' as the primary identity for the American individual
and family had been under way since the late 1800s, but it accelerated dur-
ing the years following the Second World War" (p. 341). Are citizens now
27. Id. at 13.
28. Carpenter tracks the time it took for the agency to render decisions on new drugs,
pp. 495-503, counts the references to phased clinical studies in Western medical literature, p.
293, conducts an event study in which he examines changes in pharmaceutical manufacturers'
stock prices following news from the FDA, p. 583, and engages in other counting exercises
that pack the book with information without resorting to highly complex models, see pp. 675-
85.
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nothing more than consumers? The implications, as well as the timing of
the transformation, are provocative.
Reputation and Power also contains plenty of details that could only
be interesting to an extremely small number of experts. The cast of char-
acters in Carpenter's story, ranging across borders and decades, and
including regulators, researchers, and businesspeople, is enormous. For
example, regarding Britain's approach to drug regulation, Carpenter takes
a deep immersion into the weeds of the timing of change in that country:
"Dunlop made these arguments defensively, as the 1968 changes had
come in part from dissatisfaction with his Committee's operations after
1964" (p. 699). The rest of the page delves into similarly narrow nuances
in the debate over how to reform pharmaceutical oversight in that country
(p. 699). Carpenter provides more comparative bureaucratic history, this
time involving the European Community: "It would take two decades
more-and the International Conference of Harmonization-for European
regulators to fully embrace individual case reports as part of the Common
Technical Document, but the Community's preference had been clearly
stated" (p. 703). The moment at which these international shifts occurred
on minor matters of pharmaceutical regulation did not engage me.
Finally, in the third category, I place Carpenter's view of the decline of
the agency's reputation during the Bush Administration, which comes not
merely with examples but also with historical context. The random page
generation offers this nugget: "Bush appointees to the FDA came from two
institutions that had served as homes of criticism and resistance to the Ad-
ministration in the 1970s: M. D. Anderson Hospital and the American
Enterprise Institute in Washington" (p. 741). It may be more detail than is
strictly necessary in this case, but it is interesting detail nonetheless. I can-
not assure the reader that this was the case in each of the other 801 pages of
the book.
Carpenter presents his detailed analysis with long, fact-packed sentenc-
es and huge paragraphs-on the five randomly generated pages, there were
six paragraph breaks in total. The detail, in short, is not for the faint of
heart, although since Carpenter is telling a story with a large number of
moving parts-there are a large number of audiences that have to be con-
vinced of the agency's reputation, in his view-one hopes that each of
these stories contributes to the full picture of a set of ultimately acquiescent
stakeholders to the FDA's decisions.2 9
There were also portions of the book that seemed misguided. Agency
derring-do does not only come from its esprit de corps, even when bolstered
with a powerful gatekeeping role. There is also the question of funding, and
for what it is worth, here Carpenter expresses concern that the FDA is now
partly funded by levies on drug manufacturers, which essentially pay for
their approvals (pp. 734-35). Some observers have argued that such funding
should be banned entirely in light of the risk of corruption by binding the
29. See pp. 302-14 (providing examples of Carpenter's exhaustive detail regarding all
relevant stakeholders).
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agency budget to regulated industry.3" At best, Carpenter suggests, the
pharma-pays model adopted in the Hatch-Waxman Amendments of 1996
has distorted the agency, which now has a huge new drug-approval arm and
a rather small postapproval surveillance ann; the FDA has not benefitted
from the fees for approvals and may have been collaterally defunded by
them.31
But the ability to fund oneself, even if those funds come from regulated
industry, is often the foremost way to obtain independence as an administra-
tive agency. Observers of financial regulation might tut-tut about the
dependence of banking regulators on fees from the banks that they regu-
late.32 But few scholars seem unhappy that the Federal Reserve can make
monetary policy decisions without being jerked around by congressional
purse strings.33 And they also bemoan the dependence of other agencies,
such as the SEC, on appropriations, sensitive to the fact that regulation can
fail not just because of a lack of authority but also because of a lack of re-
sources. 34 Indeed, in the aftermath of the recent financial crisis, Congress
created the Consumer Financial Protection Bureau ("CFPB") with a funding
mechanism that would make it immune to the risk of starvation by insuffi-
cient congressional appropriations.35 There are advantages to funding by
regulated entities. Indeed, law firms engaged to advise clients about compli-
ance, and even law professors engaged to grade the students whose tuition
pays their salaries, take this approach to funding.3 6
30. E.g., Marcia Angell, FDA: This Agency Can Be Dangerous, N.Y. REV. BOOKS,
Sept. 30, 2010 (reviewing Reputation and Power), available at http://www.nybooks.com/
articles/archives/2010/sep/30/agency-can-be-dangerous/.
31. Pp. 736-38. This would occur if Congress reduced funding to the agency as fee
revenue-directed exclusively to approvals-increased, as some observers have suggested
might be the case.
32. Dain C. Donelson & David Zaring, Requiem for a Regulator: The Office of Thrift
Supervision's Performance During the Financial Crisis, 89 N.C. L. REV. 1777, 1792 (2011)
(noting the critique that financial regulators are "dependent ... on fees from charter holders").
33. About the Fed, FED. RES. BANK OF S.F., http://www.frbsf.org/publications/
federalreserve/monetary/structure.html (last visited Nov. 16, 2011).
34. See, e.g., Letter from Giovanni P. Prezioso, Outgoing Chair, Exec. Council of the
Fed. Bar Ass'n's Securities Law Cmte., to Members of Congress (June 11, 2010), available at
http://www.scribd.com/doc/32916876/Federal-Bar-Association-Letter-on-S-E-C-Funding; see
also Ronald D. Orol, Five SEC Chairmen and Schumer Push for Self-Funded SEC, MARKET
WATCH (Apr. 15, 2010, 3:50 PM), http://www.marketwatch.com/story/five-sec-chairs-and-
schumer-want-self-funded-sec-2010-04-15.
35. Adam Levitin, The Political Economy of CFPB Funding, CREDIT SLIPS (Nov. 29,
2010, 8:06 PM), http://www.creditslips.org/creditslips/2010/1 1/the-political-economy-of-cfpb-
funding.html (noting that Congress adopted the CFPB's financing structure to ensure that
political disputes would not financially hobble the agency).
36. See David Zaring, Einhorn and Lewis on the Financial Crisis, THE CONGLOMER-
ATE (Jan. 4, 2009), http://www.theconglomerate.org/2009/01/einhorn-and-lew.html (noting
these examples).
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IV. JUDICIAL AND ORDINARY GOVERNANCE
Most lawyers who practice before the FDA-and there is an entire bar
that does only that-will never appear before the Court of Appeals for the
District of Columbia ("D.C. Circuit"). Nonetheless, most of the scholarship
in administrative law is premised on the idea that lawsuits will end up be-
fore that august court, and possibly also the Supreme Court, and that these
lawsuits will provide agencies with the guidance they need to perform the
delegations of power that Congress granted them. But really, only some
agencies set their clocks to judicial review. The sorts of regulation that exist
in the United States can usefully be divided into three categories, where the
relationship with the judiciary is a dividing point. The best-known
regulations are those supervised by the courts and subject to the rules of the
Administrative Procedure Act ("APA").37 The Environmental Protection
Agency ("EPA") and SEC, with their consumer protection-oriented missions,
are examples of such agencies. These agencies have an adversarial relation-
ship with regulated industry and often face challenges from active and
energetic consumer advocates or other nongovernmental organizations. 38 Liti-
gation is common, so the applicable content of rules will ultimately depend on
judicial decisionmaking. It could be called the paradigmatic model of admin-
istrative law.
The second type of administrative law regime is a more coordinated
model-that is, coordinated with the stakeholders involved in the agencies'
remit. This might be called a constituency, or interest group representation,
approach.39 The Department of Housing and Urban Development ("HUD")
and the federal government's welfare administration may be examples of
this model, where states and cities, as well as tenants and builders, partici-
pate in the policymaking and funding decisions of the agencies quite
informally or through a procurement process that rarely sees the light of
judicial day.40
Other agencies ignore the traditional administrative structure altogether.
Their often critical roles in the government proceed without much supervi-
sion by the judiciary or the Office of Management and Budget ("OMB").
These institutions include those whose regulatory mission does not easily fit
37. 5 U.S.C. §§ 551-559, 701-706 (2006).
38. See, e.g., NetCoalition v. SEC, 615 F.3d 525 (D.C. Cir. 2010) (petitioning for re-
view of an SEC order); Our Children's Earth Found. v. EPA, 527 F.3d 842 (9th Cir. 2008)
(alleging that the EPA failed to comply with the Clean Water Act).
39. See, e.g., Richard B. Stewart, Administrative Law in the Twenty-First Century, 78
N.Y.U. L. REv. 437, 442 (2003) (describing the "interest representation" model that arose in
the 1970s).
40. See Barbara L. Bezdeck, Contractual Welfare: Non-Accountability and Diminished
Democracy in Local Government Contracts for Welfare-To-Work Services, 28 FORDHAM URB.
L.J. 1559, 1559 (2001) (discussing the movement of welfare policy to the state and local lev-
els); Tim Iglesias, Housing Impact Assessments: Opening New Doors for State Housing
Regulation While Localism Persists, 82 OR. L. REv. 433, 484 (2003) (discussing the role of
local housing movements in influencing HUD policy).
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in a model of consumer protection or interest group representation. They
include the pre-APA Departments of State, Defense, and the Treasury.41
The interesting thing about the FDA is that it, like the EPA and SEC,
has a consumer protection mission, but its technical expertise has for dec-
ades kept it away from the strong oversight that the other consumer
protection agencies receive from the courts. It would seem to belong in the
paradigm of classic administrative law agencies; however, it has not had to
set its policymaking by reference to the D.C. Circuit, as have other agencies
such as the National Highway Transportation Safety Administration, which
Jerry Mashaw and David Harfst has famously suggested was hamstrung by
litigation, and eventually transformed into an inefficient, reactive recall in-
stitution rather than a proactive rulemaker 2
If the FDA exemplifies a way that an agency might win discretion for it-
self, despite being in the consumer protection business and overseeing a
well-lawyered industry, it might be worth concluding with an observation of
just how much an agency does that is foreign to courts, considering their
concern with procedural regularity over reevaluations of the substance of
the agency's decisions. The FDA has devised a drug approval process that
turns not only on what its own scientists and reviewers find, but one that
also relies on pharmaceutical manufacturers to perform the trials required to
obtain new drug approval, and on advisory commissions of leading pharma-
ceutical researchers for guidance throughout the process.43
In addition to being a scientific and technical enterprise, then, drug ap-
provals are partly privatized affairs. And this critical component of FDA
procedure lies outside the traditional focus of administrative law-that is,
judicial review of government decisions, usually performed by the D.C.
Circuit. In other words, the FDA has, possibly through reputation, and
probably also through technical decisionmaking, moved itself from the con-
sumer protection category of judge-supervised agencies into the less
supervised category-like State, Treasury, and the older departments-
partly because so much of its important work consists of the kinds of
decisions that courts are not willing to scrutinize."
41. See David Zaring, Administration by Treasury, 95 MINN. L. REV. 187, 193-94, 238
(2010) (discussing how the Treasury Department's administration differs from the strictures of
the APA and noting that "older agencies like the Departments of State and Defense" also "do
things differently" than APA-regulated agencies).
42. Jerry L. Mashaw & David L. Harfst, Inside the National Highway Traffic Safety
Administration: Legal Determinants of Bureaucratic Organization and Performance, 57 U.
CHI. L. REV. 443, 447-48 (1990).
43. Charles J. Walsh & Alissa Pyrich, Rationalizing the Regulation of Prescription
Drugs and Medical Devices: Perspectives on Private Certification and Tort Reform, 48 RUT-
GERS L. REV. 883,973 (1996).
44. Zaring, supra note 41, at 238 ("There are other agencies like Treasury, agencies that
play important roles in the government without playing important roles in the judicial (or
OMB) administration of the executive branch and administrative state. These departments
include the pre-APA agencies, and those whose regulatory mission does not comfortably fit in
a model of consumer protection or interest group representation.")
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The scholarly gaps in the study of the sort of regulation that drug regu-
lation represents may be a reasonable delegation of authority by
administrative law scholars-it could be that it makes sense to leave the
explanation of the FDA's approval process to public health, political sci-
ence, and medical school academics.
But lawyers are involved in the process of developing and obtaining ap-
proval for new drugs at every turn. Law firms devote practice groups to
managing it. Legal scholars should probably be able to make some sense of
it. One of the signal achievements of Carpenter's account is that it offers a
paradigm that does make sense of pharmaceutical regulation, one that may
be transferrable to other governance contexts. If the drug process was char-
acterized for decades by a consensual deferral to the FDA's reputation for
competent decisionmaking, then lawyers and institution builders may wish
to think carefully about how the preconditions for reputation can be built
into agencies-and maybe about whether the grant of strong legal authority
to act is a precondition or a result of that power.
CONCLUSION
Reputation and Power is a comprehensive (at times extremely compre-
hensive) retelling of the challenges of American pharmaceutical regulation
in the twentieth century and the government's response to those challenges.
Because those challenges were met again and again with successful regula-
tory responses, Carpenter's book is a rebuke to those who assume that
public administration is doomed to failure, not just because that is his incli-
nation, but also because of the book's sheer breadth. Given all the carefully
recounted interventions made by the FDA after 1938, during a golden age
of public health, it is hard to view the agency as a pure drag on the public
welfare. While no study of a single agency can definitively prove that the
agency did a good job (compared to what, one must ask), the evidence that
Carpenter assembles is massive; his success mechanism-legal power plus
extralegal reputation-is intuitive, if not definitive; and his attention to
agency outcomes as well as agency procedure is refreshing. Stories like his
may prove that there is something to the administrative state, and to careful
studies of how it has operated.
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